Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Tate, Chandra R ^a   Rhodes, Lyndsay V ^a   Segar, H Chris ^a   Driver, Jennifer L ^a   Pounder, F Nell ^a   Burow, Matthew E ^a   Collins Burow, Bridgette M ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

CDH1; E cadherin; Epithelial to mesenchymal transition; Histone deacetylase inhibitor; LBH589; Panobinostat; Triple negative breast cancer; Xenograft

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CADHERIN; PANOBINOSTAT; PROPIDIUM IODIDE; UVOMORULIN; CELL CYCLE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; FZR1 PROTEIN, MOUSE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; PROGESTERONE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL ASSAY; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION; XENOGRAFT; ANIMAL; BREAST TUMOR; CELL CYCLE; CELL TRANSFORMATION; DRUG EFFECT; GENE EXPRESSION; METABOLISM; MOUSE MUTANT; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CADHERINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; INDOLES; MICE; MICE, SCID; RANDOM ALLOCATION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861968080     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3192     Document Type: Article

References (62)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011, 61:69-90.
2. Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, Garcia-Mata J, Garcia-Teijido P, Pelaez I, Garcia-Estevez L. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 2010, 36:33-42. 10.1016/j.ctrv.2009.10.001, 19883980.
3. Beaumont T, Leadbeater M. Treatment and care of patients with metastatic breast cancer. Nurs Stand 2011, 25:49-56.
4. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14:8010-8018. 10.1158/1078-0432.CCR-08-1208, 19088017.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
6. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol 2010, 33:637-645. 10.1097/COC.0b013e3181b8afcf, 20023571.
7. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009, 9:S73-81. 10.3816/CBC.2009.s.008, 2919761, 19596646.
8. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16:1-11.
9. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010, 36:S80-86.
10. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010, 12:S3. 10.1186/bcr2732, 3005723, 21172087.
11. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005, 45:495-528. 10.1146/annurev.pharmtox.45.120403.095825, 15822187.
12. Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006, 32:157-165. 10.1016/j.ctrv.2005.12.006, 16516391.
13. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002, 13:1-13. 10.1097/00001813-200201000-00001, 11914636.
14. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006, 26:397-413. 10.1002/med.20056, 16450343.
15. Kikuchi H, Barman HK, Nakayama M, Takami Y, Nakayama T. Participation of histones, histone modifying enzymes and histone chaperones in vertebrate cell functions. Subcell Biochem 2006, 40:225-243.
16. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opin Investig Drugs 2007, 16:569-571. 10.1517/13543784.16.5.569, 17461732.
17. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552. 10.1038/sj.onc.1210620, 17694093.
18. Atadja P. Development of the pan-DAC inhibitor Panobinostat (LBH589): successes and challenges. Cancer Lett 2009, 280:233-241. 10.1016/j.canlet.2009.02.019, 19344997.
19. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5:981-989. 10.1158/1541-7786.MCR-07-0324, 17951399.
20. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P. Activity of deacetylase inhibitor Panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int J Cancer 2010, 127:2199-2208. 10.1002/ijc.25218, 20127862.
21. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66:5781-5789. 10.1158/0008-5472.CAN-05-4186, 16740717.
22. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006, 12:4628-4635. 10.1158/1078-0432.CCR-06-0511, 16899611.
23. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, Kobayashi K, Yamamoto N. A phase I study of oral Panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 2012, 30:1096-1106. 10.1007/s10637-011-9666-9, 21484248.
24. Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G. Cytotoxic activity of the histone deacetylase inhibitor Panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 2012, 130:694-704. 10.1002/ijc.26057, 21400508.
25. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM. The HDAC inhibitor Panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009, 8:2221-2231.
26. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009, 5:601-612. 10.2217/fon.09.36, 19519200.
27. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006, 66:11298-11304. 10.1158/0008-5472.CAN-06-0049, 17145876.
28. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449. 10.1182/blood-2006-04-016055, 1895432, 16728695.
29. Maiso P, Colado E, Ocio EM, Garayoa M, Martin J, Atadja P, Pandiella A, San-Miguel JF. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia 2009, 23:2265-2274. 10.1038/leu.2009.182, 19812608.
30. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010, 66:181-189. 10.1007/s00280-010-1289-x, 20217089.
31. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008, 14:4500-4510. 10.1158/1078-0432.CCR-07-4262, 18628465.
32. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012, 107:133-138. 10.1007/s11060-011-0717-z, 21984064.
33. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010, 10:462-470.
34. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 2010, 121:293-300. 10.1007/s10549-009-0458-2, 19597705.
35. Semb H, Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum Genet 1998, 63:1588-1593. 10.1086/302173, 1377629, 9837810.
36. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213:374-383. 10.1002/jcp.21223, 17680632.
37. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008, 25:629-642. 10.1007/s10585-008-9170-6, 18461285.
38. Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 1999, 59:947-952.
39. Kalin JH, Butler KV, Kozikowski AP. Creating zinc monkey wrenches in the treatment of epigenetic disorders. Curr Opin Chem Biol 2009, 13:263-271. 10.1016/j.cbpa.2009.05.007, 19541531.
40. Terpos E. The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. Leuk Res 2010, 35:295-296.
41. Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A, Kuwayama Y, Togitani K, Koeffler HP, Taguchi H. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008, 32:287-96. 10.1016/j.leukres.2007.05.026, 17644177.
42. Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T, Gahr S, Quint K, Meissnitzer M, Alinger B, Montalbano R, Sass G, Hohenstein B, Hahn EG, Ocker M. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol 2010, 32:285-300.
43. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 2007, 6:64-69. 10.4161/cbt.6.1.3549, 17172825.
44. Fortunati N, Catalano MG, Marano F, Mugoni V, Pugliese M, Bosco O, Mainini F, Boccuzzi G. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res Treat 2010, 124:667-675. 10.1007/s10549-010-0789-z, 20213084.
45. Budman DR, Tai J, Calabro A, John V. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Invest New Drugs 2011, 29:1224-1229. 10.1007/s10637-010-9467-6, 20533074.
46. Storch K, Eke I, Borgmann K, Krause M, Richter C, Becker K, Schröck E, Cordes N. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 2010, 70:3925-3934. 10.1158/0008-5472.CAN-09-3848, 20442295.
47. Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja PW, Bhalla KN. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther 2012, 11:973-983. 10.1158/1535-7163.MCT-11-0979, 22367781.
48. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by induction of autophagy. Breast Cancer Res Treat 2011, 130:437-447. 10.1007/s10549-011-1364-y, 21298336.
49. Chen S, Ye J, Kijima I, Evans D. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci USA 2010, 107:11032-11037. 10.1073/pnas.1000917107, 2890707, 20534486.
50. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009, 15:6148-6157. 10.1158/1078-0432.CCR-09-1039, 19789319.
51. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Fieuws S, Machiels K, Atadja P, Wozniak A, Faa G, Schoffski P. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009, 15:4066-4076. 10.1158/1078-0432.CCR-08-2588, 19509176.
52. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
53. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
54. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001, 61:5168-5178.
55. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994, 31:325-335. 10.1007/BF00666165, 7881109.
56. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96. 10.1016/j.molonc.2007.02.004, 2391005, 18516279.
57. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res 2011, 13:226. 10.1186/bcr3037, 3326549, 22078097.
58. Ouyang G. Epithelial-Mesenchymal Transition and Cancer Stem Cells. Cancer Stem Cells - The Cutting Edge 2011, 167-188. Stanley Shostak.
59. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428. 10.1172/JCI39104, 2689101, 19487818.
60. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011, 13:202. 3109556, 21392411.
61. Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, Arroyo CD, Brogi E, Morrow M, King TA. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat 2012, 132:641-652. 10.1007/s10549-011-1860-0, 22080244.
62. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, Cleary KR, Tahara E, Fidler IJ. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999, 5:25-33.